APEIRON Biologics AG appointed Peter Llewellyn-Davies as new Chief Financial Officer and Chief Business Officer. The biotech and financial expert Llewellyn-Davies is considered an internationally experienced and recognized transaction specialist. After marketing approval of APEIRON’s immunotherapeutic against neuroblastoma the appointment of this strategically important role should prepare the company for its next phase of growth….

The European Investment Bank (EIB) will provide financing of EUR 25 million to the Austrian biotech company Apeiron Biologics AG (Apeiron). The financing will support the development of new pharmaceutical products to treat cancer, particularly a rare type affecting children. The transaction with Apeiron was made possible by the support of the “European Fund for…

On May 8, 2017, The European Commission has granted marketing authorization for “Dinutuximab beta Apeiron”, an antibody-based immunotherapy the rare pediatric cancer neuroblastoma. Thanks to the Vienna-based Biotech company Apeiron Biologics AG (“Apeiron”) patients in Europe are now offered an additional treatment option with a promising therapy – a result of a collaborative effort of…

APEIRON Biologics AG today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of dinutuximab beta (APN311; ch14.18/CHO) for immunotherapy of high risk neuroblastoma. Press release Presseaussendung

APEIRON Biologics AG grants EUSA Pharma, UK exclusive global commercialization rights to the oncology product ISQETTE®. ISQETTE® is an antibody-based immunotherapy with orphan drug designation for the treatment of pediatric neuroblastoma. The therapy has been developed by APEIRON together with an academic network including the St. Anna Children’s Cancer Research Institute in Vienna. Press release…

Under the terms of the agreement, Apeiron obtains worldwide exclusive rights to develop and commercialize active cellular immunotherapies under the licensed patents, which cover the inhibition of Cbl-b in T cells for the treatment of cancer. Press release Presseaussendung

Evotec AG, Apeiron Biologics AG, and Sanofi to jointly develop novel small molecule-based cancer immunotherapies. Press release Presseaussendung

Apeiron’s project APN401, based on the collection, stimulation and subsequent re-administration of a patient’s immune cells, is being investigated in a clinical phase I trial performed at a renowned, academic medical center in the United States. Press release Presseaussendung